Clinical Trials Directory

Trials / Completed

CompletedNCT02473458

Efficacy of Whole Extract of Licorice in Neurological Improvement of Patients After Acute Ischemic Stroke

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
75 (actual)
Sponsor
Shiraz University of Medical Sciences · Academic / Other
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

Stroke is one of the most important causes of mortality and disability both in developed and developing countries. The only food and drug administration (FDA) approved therapy for acute stroke is recombinant tissue plasminogen activator (rtPA). But narrow therapeutic window has limited the usefulness of thrombolytic therapy. Therefore, finding effective neuroprotective drugs for the patients for whom thrombolysis is contraindicated or not feasible seemed to be mandatory in the world of cerebrovascular medicine. Licorice, extracted from root of a plant scientifically known as Glycyrrhiza glabra, is used in food industries. Certain medical properties has been contributed to licorice and specifically to its active chemical components such as flavonoids and glycyrrhizic acid (GA). GA has been revealed to assert its anti-inflammatory effect by suppression of NF-κB, a key component of lipopolysaccharide-induced inflammatory response. Neuroprotective characteristics of GA has been widely investigated in recent studies. In the present study, the investigators verified the efficacy and safety of oral administration of two different doses licorice extract in the patients with acute ischemic stroke, in a double-blind randomized controlled trial.

Conditions

Interventions

TypeNameDescription
DRUGLicorice whole extractPatients randomly received one of below capsules labeled with codes during the first 24 hours after stroke attack: 1. Starch-filled capsules (as placebo) 2. 450 mg whole licorice extract capsules 3. 900 mg whole licorice extract capsules
DRUGPlacebo

Timeline

Start date
2012-06-01
Primary completion
2013-06-01
Completion
2014-06-01
First posted
2015-06-16
Last updated
2015-06-16

Locations

1 site across 1 country: Iran

Source: ClinicalTrials.gov record NCT02473458. Inclusion in this directory is not an endorsement.